MX2008002019A - Moduladores del regulador de conductancia transmembrana de fibrosis quistica. - Google Patents
Moduladores del regulador de conductancia transmembrana de fibrosis quistica.Info
- Publication number
- MX2008002019A MX2008002019A MX2008002019A MX2008002019A MX2008002019A MX 2008002019 A MX2008002019 A MX 2008002019A MX 2008002019 A MX2008002019 A MX 2008002019A MX 2008002019 A MX2008002019 A MX 2008002019A MX 2008002019 A MX2008002019 A MX 2008002019A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- cystic fibrosis
- fibrosis transmembrane
- conductance regulator
- transmembrane conductance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Abstract
La presente invencion se relaciona con moduladores del Regulador de Conductancia Transmembrana de Fibrosis Quistica ("CFTR"), las composiciones de los mismos, y los metodos con los mismos. La presente invencion tambien se relaciona con metodos para el tratamiento de enfermedades provocadas por el CFTR utilizando estos moduladores.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70738005P | 2005-08-11 | 2005-08-11 | |
US73247605P | 2005-11-02 | 2005-11-02 | |
PCT/US2006/031457 WO2007021982A2 (en) | 2005-08-11 | 2006-08-11 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008002019A true MX2008002019A (es) | 2008-04-16 |
Family
ID=37663354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008002019A MX2008002019A (es) | 2005-08-11 | 2006-08-11 | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
Country Status (13)
Country | Link |
---|---|
US (5) | US7999113B2 (es) |
EP (1) | EP1912983B1 (es) |
JP (4) | JP5143738B2 (es) |
KR (1) | KR20080053297A (es) |
AT (1) | ATE512145T1 (es) |
AU (1) | AU2006279810B2 (es) |
CA (1) | CA2618057A1 (es) |
IL (1) | IL189178A0 (es) |
MX (1) | MX2008002019A (es) |
NO (1) | NO20081280L (es) |
NZ (1) | NZ566208A (es) |
RU (1) | RU2008109031A (es) |
WO (1) | WO2007021982A2 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP1664006A2 (en) | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2545719A1 (en) * | 2003-11-14 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
EP1912983B1 (en) * | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
HUE032640T2 (en) * | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7691902B2 (en) * | 2005-12-28 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
HUE055205T2 (hu) * | 2006-04-07 | 2021-11-29 | Vertex Pharma | ATP-kötõ kazetta transzporterek modulátorainak elõállítása |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8318935B2 (en) | 2007-05-07 | 2012-11-27 | Novartis Ag | Organic compounds 75074 |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
ES2578735T3 (es) | 2007-08-24 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística |
US8507524B2 (en) | 2007-11-16 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette-transporters |
BRPI0820681A2 (pt) * | 2007-12-07 | 2019-09-24 | Vertex Pharma | formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico |
CN101910134B (zh) | 2007-12-07 | 2014-03-19 | 沃泰克斯药物股份有限公司 | 环烷基甲酰氨基-吡啶苯甲酸类的生产方法 |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
US8507534B2 (en) | 2007-12-07 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
JP5455922B2 (ja) | 2007-12-10 | 2014-03-26 | ノバルティス アーゲー | 有機化合物 |
CN103382201B (zh) | 2008-02-28 | 2016-12-28 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
US8227615B2 (en) | 2008-03-31 | 2012-07-24 | Vertex Pharmaceutical Incorporated | Pyridyl derivatives as CFTR modulators |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
MX2011003249A (es) | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
AR074060A1 (es) * | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
LT2821400T (lt) | 2009-03-20 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
AR081069A1 (es) | 2010-04-07 | 2012-06-06 | Vertex Pharma | Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico |
CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2776427B1 (en) | 2011-11-08 | 2017-02-01 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US10006904B2 (en) | 2011-12-19 | 2018-06-26 | Umc Utrecht Holding B.V. | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
DK2978748T3 (en) * | 2013-03-27 | 2017-07-24 | Pfizer Ireland Pharmaceuticals | Process and intermediates for the preparation of pregabalin |
WO2015073231A1 (en) | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
KR102447581B1 (ko) | 2014-04-15 | 2022-09-28 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물 |
PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
KR101721029B1 (ko) | 2014-10-16 | 2017-03-29 | 연세대학교 산학협력단 | 인돌리지노[3,2-c]퀴놀린 유도체, 이의 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 낭포성 섬유증 예방 또는 치료용 약학조성물 |
SI3212189T1 (sl) * | 2014-10-31 | 2020-11-30 | Abbvie Overseas S.A R.L. | Substituirani kromani in postopki uporabe |
SI3221692T1 (sl) | 2014-11-18 | 2021-11-30 | Vertex Pharmaceuticals Inc. | Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo |
US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2018064632A1 (en) | 2016-09-30 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107100A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS |
WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
PT3752510T (pt) | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
MX2021002653A (es) | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares. |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
BR112023022315A2 (pt) | 2021-04-29 | 2024-02-20 | Novartis Ag | Quimeras direcionadas à desubiquitinase e métodos relacionados |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6426331B1 (en) * | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
ES2226622T3 (es) * | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
CA2442654A1 (en) * | 2001-04-10 | 2002-10-10 | Transtech Pharma, Inc. | Probes, systems, and methods for drug discovery |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
WO2004111014A1 (en) * | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
EP1664006A2 (en) * | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
CN1886393A (zh) * | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp-结合弹夹转运蛋白的调控剂 |
CA2545719A1 (en) * | 2003-11-14 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP1891018B1 (en) * | 2005-05-24 | 2011-11-16 | Vertex Pharmaceuticals, Inc. | Modulators of atp-binding cassette transporters |
EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
US8314256B2 (en) | 2005-10-06 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
HUE032640T2 (en) * | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
CN101374849A (zh) | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 |
WO2007075946A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
US7691902B2 (en) * | 2005-12-28 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
HUE055205T2 (hu) | 2006-04-07 | 2021-11-29 | Vertex Pharma | ATP-kötõ kazetta transzporterek modulátorainak elõállítása |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
AU2008256717B2 (en) | 2007-05-25 | 2013-11-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
ES2578735T3 (es) | 2007-08-24 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística |
AU2008298545B2 (en) | 2007-09-14 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
JP2010540417A (ja) | 2007-09-14 | 2010-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
US8507524B2 (en) | 2007-11-16 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette-transporters |
US8507534B2 (en) | 2007-12-07 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN101910134B (zh) | 2007-12-07 | 2014-03-19 | 沃泰克斯药物股份有限公司 | 环烷基甲酰氨基-吡啶苯甲酸类的生产方法 |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
BRPI0820681A2 (pt) * | 2007-12-07 | 2019-09-24 | Vertex Pharma | formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico |
JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
CN103382201B (zh) | 2008-02-28 | 2016-12-28 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
US8227615B2 (en) | 2008-03-31 | 2012-07-24 | Vertex Pharmaceutical Incorporated | Pyridyl derivatives as CFTR modulators |
US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
ES2857152T3 (es) | 2008-08-13 | 2021-09-28 | Vertex Pharma | Composición farmacéutica y administraciones de la misma |
MX2011003249A (es) | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
AR074060A1 (es) * | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
EP2358721B1 (en) | 2008-10-23 | 2014-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
DK2358680T3 (da) * | 2008-10-23 | 2013-06-24 | Vertex Pharma | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid |
US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
LT2821400T (lt) | 2009-03-20 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas |
RU2518897C2 (ru) | 2009-03-20 | 2014-06-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные 3-карбоксамида-4-оксохинолина, полезные в качестве модуляторов регулятора трансмембранной проводимости кистозного фиброза |
AU2010295461B2 (en) | 2009-09-17 | 2016-03-03 | Vertex Pharmaceuticals Incorporated | Process for preparing azabicyclic compounds |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
CN102648182A (zh) | 2009-10-23 | 2012-08-22 | 沃泰克斯药物股份有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
UA108087C2 (uk) | 2009-10-23 | 2015-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду |
AU2011227021A1 (en) | 2010-03-19 | 2012-10-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
RU2711481C2 (ru) | 2010-03-25 | 2020-01-17 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
AR081069A1 (es) | 2010-04-07 | 2012-06-06 | Vertex Pharma | Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico |
CA2796646A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2796642A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
NZ603386A (en) | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
US20120046330A1 (en) | 2010-08-23 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
RU2013113627A (ru) | 2010-08-27 | 2014-10-10 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CA2853299A1 (en) | 2011-11-02 | 2013-05-10 | Vertex Pharmaceuticals Incorporated | Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases |
EP2776427B1 (en) | 2011-11-08 | 2017-02-01 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA3128556A1 (en) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
SG10201703452PA (en) | 2012-11-02 | 2017-06-29 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
-
2006
- 2006-08-11 EP EP06801307A patent/EP1912983B1/en active Active
- 2006-08-11 NZ NZ566208A patent/NZ566208A/en not_active IP Right Cessation
- 2006-08-11 US US11/503,449 patent/US7999113B2/en active Active
- 2006-08-11 AU AU2006279810A patent/AU2006279810B2/en not_active Ceased
- 2006-08-11 CA CA002618057A patent/CA2618057A1/en not_active Abandoned
- 2006-08-11 KR KR20087005989A patent/KR20080053297A/ko not_active Application Discontinuation
- 2006-08-11 RU RU2008109031/04A patent/RU2008109031A/ru not_active Application Discontinuation
- 2006-08-11 JP JP2008526246A patent/JP5143738B2/ja active Active
- 2006-08-11 WO PCT/US2006/031457 patent/WO2007021982A2/en active Application Filing
- 2006-08-11 MX MX2008002019A patent/MX2008002019A/es not_active Application Discontinuation
- 2006-08-11 AT AT06801307T patent/ATE512145T1/de not_active IP Right Cessation
-
2008
- 2008-02-03 IL IL189178A patent/IL189178A0/en unknown
- 2008-03-11 NO NO20081280A patent/NO20081280L/no not_active Application Discontinuation
-
2011
- 2011-07-08 US US13/178,677 patent/US8586615B2/en active Active
-
2012
- 2012-10-29 JP JP2012237953A patent/JP2013018795A/ja not_active Withdrawn
-
2013
- 2013-10-16 US US14/055,247 patent/US8962856B2/en active Active
-
2014
- 2014-06-03 JP JP2014114689A patent/JP5850983B2/ja active Active
-
2015
- 2015-01-16 US US14/598,560 patent/US9351962B2/en active Active
- 2015-04-08 JP JP2015078955A patent/JP2015127347A/ja not_active Withdrawn
-
2016
- 2016-04-22 US US15/136,159 patent/US9856248B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5143738B2 (ja) | 2013-02-13 |
ATE512145T1 (de) | 2011-06-15 |
JP2015127347A (ja) | 2015-07-09 |
JP2014156494A (ja) | 2014-08-28 |
EP1912983B1 (en) | 2011-06-08 |
RU2008109031A (ru) | 2009-09-20 |
US20150126566A1 (en) | 2015-05-07 |
US9351962B2 (en) | 2016-05-31 |
JP5850983B2 (ja) | 2016-02-03 |
US7999113B2 (en) | 2011-08-16 |
JP2009504670A (ja) | 2009-02-05 |
US20140121381A1 (en) | 2014-05-01 |
US20160237079A1 (en) | 2016-08-18 |
NZ566208A (en) | 2010-09-30 |
CA2618057A1 (en) | 2007-02-22 |
EP1912983A2 (en) | 2008-04-23 |
US8586615B2 (en) | 2013-11-19 |
US8962856B2 (en) | 2015-02-24 |
US9856248B2 (en) | 2018-01-02 |
AU2006279810B2 (en) | 2011-10-27 |
US20080161371A1 (en) | 2008-07-03 |
WO2007021982A3 (en) | 2007-05-03 |
KR20080053297A (ko) | 2008-06-12 |
WO2007021982A2 (en) | 2007-02-22 |
JP2013018795A (ja) | 2013-01-31 |
IL189178A0 (en) | 2008-06-05 |
AU2006279810A1 (en) | 2007-02-22 |
US20170174675A9 (en) | 2017-06-22 |
NO20081280L (no) | 2008-05-09 |
US20120010257A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008002019A (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. | |
HK1138586A1 (en) | Modulators of cftr cftr | |
HK1140475A1 (en) | Azaindole derivatives as cftr modulators | |
WO2006099256A3 (en) | Modulators of atp-binding cassette transporters | |
IN2014KN02423A (es) | ||
NZ583878A (en) | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) | |
WO2007044560A3 (en) | Modulators of atp-binding cassette transporters | |
MX365890B (es) | Moduladores de transportadores con casete de unión con atp. | |
MX357497B (es) | Moduladores de transportadores de casete de union a atp. | |
WO2009038913A3 (en) | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | |
DE602004022819D1 (de) | Von atp-bindende kassette transportern | |
AU2010327993A8 (en) | 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters | |
MX2011004375A (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. | |
WO2010054138A3 (en) | Modulators of atp-binding cassette transporters | |
WO2009108657A3 (en) | Heteroaryl derivatives as cftr modulators | |
WO2006127588A3 (en) | Modulators of atp-binding cassette transporters | |
HK1148006A1 (en) | Isoquinoline modulators of atp-binding cassette transporters atp | |
WO2004108133A3 (en) | Modulators of vr1 receptor | |
WO2007076070A3 (en) | Modulators of muscarinic receptors | |
TW200621244A (en) | Modulators of muscarinic receptors | |
WO2006058294A3 (en) | Modulators of muscarinic receptors | |
WO2005030188A3 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
WO2006058303A3 (en) | Modulators of muscarinic receptors | |
EP2502913A3 (en) | Modulators of ATP-binding cassette transporters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |